Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $2.75
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$5.27M
Enterprise Value-$2.17
Total Cash (Recent Filing)$5.20M
Total Debt (Recent Filing)$420.15K
Price to Earnings (P/E)―
Beta3.40
Next Earnings
Sep 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1142.54
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio materially reduces refinancing and interest-service risk, giving the company greater financial flexibility to fund R&D or endure operational losses. This conservatively financed balance sheet supports resilience across multi-quarter development cycles.
Merger Progress / Strategic PivotAdvancing the reverse merger (S-4 filing, amendment, board approvals and target close) is a structural shift: it creates a Nasdaq-listed migraine-focused biotech, unlocks planned pre-closing financings and positions the combined entity to access substantial growth capital and corporate resources.
Multiple Revenue PathsA business model combining manufacturing capabilities with drug discovery/collaboration potential provides durable optionality: manufacturing can generate near-term commercial revenues while licensing or partnerships can monetize R&D programs over longer timelines, diversifying cash flow sources.
Bears Say
Severe Cash BurnDeep and accelerating negative operating and free cash flows imply the company is consuming cash faster than historical norms, raising material funding risk across the next several quarters. This structural cash shortfall pressures the need for dilutive financing or strategic transactions to sustain operations.
Low Margins & Continued LossesPersistently low gross margins and negative operating profit indicate the business is not yet generating sustainable unit economics. Structural margin weakness limits the company's ability to reach breakeven without material product mix changes, cost reductions, or outsized revenue ramps from new programs.
Dilution / Governance ShiftThe reverse-merger terms and recent option repricings create substantial dilution and a near-total ownership transfer to incoming stakeholders. That structural change reduces legacy shareholder economics and cedes strategic control, altering incentives and exposing holders to concentrated governance decisions by new majority owners.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $2.75 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $5.27M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 18, 2026 which is in 63 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.733 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 3,314,063 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
59.88% Insiders
6.80% Other Institutional Investors
33.33% Public Companies and
Individual Investors